Knockdown of Leptin Receptor Affects Macrophage Phenotype in the Tumor Microenvironment Inhibiting Breast Cancer Growth and Progression.
breast cancer
immune checkpoint blockade
leptin
leptin receptor
tumor associated macrophages
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Jul 2020
27 Jul 2020
Historique:
received:
16
06
2020
revised:
17
07
2020
accepted:
23
07
2020
entrez:
31
7
2020
pubmed:
31
7
2020
medline:
31
7
2020
Statut:
epublish
Résumé
Aberrant leptin (Ob) signaling, a hallmark of obesity, has been recognized to influence breast cancer (BC) biology within the tumor microenvironment (TME). Here, we evaluated the impact of leptin receptor (ObR) knockdown in affecting BC phenotype and in mediating the interaction between tumor cells and macrophages, the most abundant immune cells within the TME. The stable knockdown of ObR (ObR sh) in ERα-positive and ERα-negative BC cells turned the tumor phenotype into a less aggressive one, as evidenced by in vitro and in vivo models. In xenograft tumors and in co-culture experiments between circulating monocytes and BC cells, the absence of ObR reduced the recruitment of macrophages, and also affected their cytokine mRNA expression profile. This was associated with a decreased expression and secretion of monocyte chemoattractant protein-1 in ObR sh clones. The loss of Ob/ObR signaling modulated the immunosuppressive TME, as shown by a reduced expression of programmed death ligand 1/programmed cell death protein 1/arginase 1. In addition, we observed increased phagocytic activity of macrophages compared to control Sh clones in the presence of ObR sh-derived conditioned medium. Our findings, addressing an innovative role of ObR in modulating immune TME, may open new avenues to improve BC patient health care.
Identifiants
pubmed: 32727138
pii: cancers12082078
doi: 10.3390/cancers12082078
pmc: PMC7464041
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : #18602
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : PRIN2015#2015B7M39T
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : #21414
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : PRIN 2017 # 2017EKMFTN_001
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : PRIN 2017 # 2017WNKSLR_005
Références
Am J Pathol. 2019 Mar;189(3):687-698
pubmed: 30610844
Cells. 2020 Jan 10;9(1):
pubmed: 31936729
Mol Cell Endocrinol. 2014 Jan 25;382(1):570-582
pubmed: 23562747
Biochim Biophys Acta. 2011 Apr;1815(2):197-213
pubmed: 21193018
Mol Cancer. 2019 Dec 5;18(1):177
pubmed: 31805946
Immunol Lett. 1999 May 3;68(1):141-6
pubmed: 10397169
Int J Cancer. 2009 Sep 15;125(6):1276-84
pubmed: 19479998
Immunotherapy. 2017 Mar;9(3):289-302
pubmed: 28231720
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Exp Cell Res. 1999 Nov 1;252(2):439-48
pubmed: 10527634
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Clin Cancer Res. 2016 May 1;22(9):2271-82
pubmed: 26667489
Oncol Lett. 2019 Nov;18(5):5399-5407
pubmed: 31612048
Immunol Rev. 2009 May;229(1):114-25
pubmed: 19426218
J Immunol. 2003 Aug 1;171(3):1232-9
pubmed: 12874210
Cancer Res. 2011 Jul 1;71(13):4707-19
pubmed: 21555371
Biochem Biophys Res Commun. 2003 Jan 10;300(2):247-52
pubmed: 12504075
Biochim Biophys Acta. 2016 Jan;1865(1):23-34
pubmed: 26145884
Cell Death Dis. 2016 Feb 25;7:e2115
pubmed: 26913605
Cell Signal. 2010 Sep;22(9):1350-62
pubmed: 20466060
Oncotarget. 2016 Jan 12;7(2):1262-75
pubmed: 26556856
Biochim Biophys Acta Mol Cell Res. 2019 Dec;1866(12):118526
pubmed: 31398408
Trends Mol Med. 2016 Feb;22(2):88-98
pubmed: 26776093
Sci Signal. 2012 Jun 26;5(230):ra46
pubmed: 22740686
Eur J Immunol. 2006 Dec;36(12):3118-30
pubmed: 17125143
Int J Clin Exp Pathol. 2015 Jun 01;8(6):6656-64
pubmed: 26261547
Lab Invest. 1994 Jul;71(1):5-16
pubmed: 7518882
Science. 2017 May 5;356(6337):513-519
pubmed: 28473584
PLoS One. 2011;6(6):e21467
pubmed: 21731759
Cancer Causes Control. 2008 Dec;19(10):1319-28
pubmed: 18752034
Nature. 1987 Oct 15-21;329(6140):630-2
pubmed: 2443857
Cancers (Basel). 2015 Jan 15;7(1):143-78
pubmed: 25599228
J Leukoc Biol. 1995 May;57(5):747-51
pubmed: 7539028
Front Endocrinol (Lausanne). 2017 Feb 21;8:30
pubmed: 28270795
Science. 2017 Mar 31;355(6332):1428-1433
pubmed: 28280247
Oncotarget. 2016 Oct 4;7(40):65441-65453
pubmed: 27588409
Cancer Res. 1996 Oct 15;56(20):4625-9
pubmed: 8840975
Lancet. 2016 Apr 2;387(10026):1377-1396
pubmed: 27115820
Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1686-91
pubmed: 16030102
Clin Exp Immunol. 2002 Jul;129(1):119-24
pubmed: 12100031
JAMA Oncol. 2015 Aug;1(5):611-21
pubmed: 26182172
Histol Histopathol. 2018 Feb;33(2):133-145
pubmed: 28681373
NPJ Breast Cancer. 2016;2:
pubmed: 26998515
Front Oncol. 2014 Nov 26;4:340
pubmed: 25505738
Semin Cancer Biol. 2020 Feb;60:274-284
pubmed: 31491560
Cell Mol Immunol. 2018 Apr;15(4):335-345
pubmed: 29375123
Hum Reprod Update. 2000 May-Jun;6(3):290-300
pubmed: 10874574
Am J Pathol. 2009 Sep;175(3):1270-80
pubmed: 19644018
Cancer Res. 2006 Jan 15;66(2):605-12
pubmed: 16423985
Clin Cancer Res. 2000 Aug;6(8):3282-9
pubmed: 10955814
Curr Opin Pharmacol. 2016 Dec;31:83-89
pubmed: 27816025
Lancet. 2014 Aug 30;384(9945):766-81
pubmed: 24880830
Cancer Res. 2012 Mar 15;72(6):1416-27
pubmed: 22282662
FASEB J. 2018 Aug;32(8):4343-4355
pubmed: 29513571
Cancers (Basel). 2019 Oct 01;11(10):
pubmed: 31581535
Sci Rep. 2016 Feb 22;6:21782
pubmed: 26899873
Nat Rev Endocrinol. 2011 Nov 15;8(5):263-75
pubmed: 22083089
Biomolecules. 2020 Apr 03;10(4):
pubmed: 32260113
Int J Oncol. 2016 Jun;48(6):2479-87
pubmed: 27082857
Onco Targets Ther. 2014 Aug 21;7:1475-80
pubmed: 25187727
Am J Pathol. 2016 May;186(5):1328-39
pubmed: 26968343
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
Cancer Cell. 2014 Nov 10;26(5):623-37
pubmed: 25446896
Biochim Biophys Acta. 2012 Apr;1825(2):207-22
pubmed: 22289780
Free Radic Res. 2003 Aug;37(8):809-14
pubmed: 14567439
J Cell Mol Med. 2015 May;19(5):1122-32
pubmed: 25721149
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
J Immunol. 2005 Jun 1;174(11):6820-8
pubmed: 15905523
Cancer. 2001 Sep 1;92(5):1085-91
pubmed: 11571719
Cancer Res. 2004 Aug 15;64(16):5839-49
pubmed: 15313928
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6303-8
pubmed: 19332785
Cancer Metastasis Rev. 2013 Jun;32(1-2):303-15
pubmed: 23114846
Oncogene. 2017 Nov 16;36(46):6420-6431
pubmed: 28745321
Cancers (Basel). 2019 Jan 09;11(1):
pubmed: 30634494
Nanomedicine (Lond). 2014 Apr;9(5):695-707
pubmed: 24827844
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16158-63
pubmed: 17911267
Pancreas. 2002 Mar;24(2):169-78
pubmed: 11854622
Oncogene. 2009 Jul 30;28(30):2710-22
pubmed: 19483731
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
Oncoimmunology. 2015 Aug 31;5(3):e1085146
pubmed: 27141339
Thromb Res. 2012 May;129(5):641-7
pubmed: 21840575
J Biol Chem. 2006 Sep 8;281(36):26320-8
pubmed: 16825198
Cancer Lett. 2008 Aug 28;267(2):271-85
pubmed: 18439751
J Pathol. 2000 Mar;190(4):430-6
pubmed: 10699991